ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Geriatric Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,338Medicare Part D Prescriptions Filled, Including Refills

Rank: 29 out of 117

$487K Total Retail Price of All Prescriptions

Rank: 34 out of 117

366 Patients Receiving at Least One Drug in Part D
100%Patients 65 Years and Older
66% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Illinois
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 366 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

11% of this provider’s 366 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

1% of this provider’s 9,335 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$52 was the average price of a prescription from this provider, compared to $58 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 24.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Illinois
LEVOTHYROXINE SODIUM 416 416 1 2
AMLODIPINE BESYLATE 412 412 2 5
WARFARIN SODIUM 406 406 3 9
FUROSEMIDE 380 380 4 3
LISINOPRIL 294 294 5 4
OMEPRAZOLE 281 281 6 6
SIMVASTATIN 274 274 7 1
IPRATROPIUM-ALBUTEROL 255 255 8 75
METOPROLOL TARTRATE 236 236 9 8
HYDROCODONE-ACETAMINOPHEN 169 169 S3 10 7
DONEPEZIL HCL 153 153 11 10
POLYETHYLENE GLYCOL 3350 145 145 12 32
SERTRALINE HCL 145 145 12 22
KLOR-CON M20 140 140 14 34
METFORMIN HCL 131 131 15 11
ATENOLOL 130 130 16 20
BUMETANIDE 123 123 17 96
FAMOTIDINE 114 114 18 38
ATORVASTATIN CALCIUM 111 111 19 15
CARVEDILOL 101 101 20 24
POTASSIUM CHLORIDE 101 101 20 17
METOPROLOL SUCCINATE 101 101 20 12
DIOVAN 99 99 23 31
DIGOXIN 98 98 24 35
CITALOPRAM HBR 93 93 25 19
NOVOLIN 70-30 86 86 26 140
NITROGLYCERIN PATCH 83 83 27 192
GABAPENTIN 83 83 27 16
CARBIDOPA-LEVODOPA 81 79 29 45
TRAMADOL HCL 80 80 30 18
PANTOPRAZOLE SODIUM 80 80 30 26
LEVOFLOXACIN 77 77 32 80
TAMSULOSIN HCL 75 75 33 28
QUETIAPINE FUMARATE 73 73 34 36
PREDNISONE 72 72 35 49
NAMENDA 65 65 36 14
KLOR-CON M10 63 63 37 89
LIDODERM 63 63 37 46
ESCITALOPRAM OXALATE 61 61 39 42
HYDROCORTISONE 60 60 40 138
LOSARTAN POTASSIUM 60 60 40 23
ALLOPURINOL 55 55 42 48
TRIAMCINOLONE ACETONIDE 54 54 43 82
SPIRONOLACTONE 53 53 44 53
CLOPIDOGREL 52 52 45 30
MIRTAZAPINE 50 50 46 25
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.